Pliant Therapeutics Inc (NASDAQ: PLRX) on Friday, plunged -34.81% from the previous trading day, before settling in for the closing price of $11.95. Within the past 52 weeks, PLRX’s price has moved between $10.22 and $18.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -41.09%. The company achieved an average annual earnings per share of -32.31%. With a float of $53.50 million, this company’s outstanding shares have now reached $60.85 million.
Considering the fact that the conglomerate employs 158 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 66.96%, operating margin of -4588.47%, and the pretax margin is -4166.96%.
Pliant Therapeutics Inc (PLRX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Pliant Therapeutics Inc is 12.08%, while institutional ownership is 96.28%. The most recent insider transaction that took place on Jan 17 ’25, was worth 587,150. In this transaction President and CEO of this company sold 52,419 shares at a rate of $11.20, taking the stock ownership to the 430,517 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Financial Officer sold 20,148 for $11.20, making the entire transaction worth $225,680. This insider now owns 262,608 shares in total.
Pliant Therapeutics Inc (PLRX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -32.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -13.88% during the next five years compared to -22.68% drop over the previous five years of trading.
Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators
Pliant Therapeutics Inc (PLRX) is currently performing well based on its current performance indicators. A quick ratio of 10.26 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.34, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -3.99 in one year’s time.
Technical Analysis of Pliant Therapeutics Inc (PLRX)
Compared to the last year’s volume of 0.73 million, its volume of 1.66 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 53.63%. Additionally, its Average True Range was 1.03.
During the past 100 days, Pliant Therapeutics Inc’s (PLRX) raw stochastic average was set at 6.84%, which indicates a significant decrease from 10.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 183.82% in the past 14 days, which was higher than the 93.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.74, while its 200-day Moving Average is $12.77. Nevertheless, the first resistance level for the watch stands at $10.77 in the near term. At $13.76, the stock is likely to face the second major resistance level. The third major resistance level sits at $15.55. If the price goes on to break the first support level at $5.99, it is likely to go to the next support level at $4.20. Should the price break the second support level, the third support level stands at $1.21.
Pliant Therapeutics Inc (NASDAQ: PLRX) Key Stats
Market capitalization of the company is 474.05 million based on 60,854K outstanding shares. Right now, sales total 1,580 K and income totals -161,340 K. The company made 0 K in profit during its latest quarter, and -57,760 K in sales during its previous quarter.
